Blood Cancer
EA9213
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Physician Fact Sheet
